Navigation Links
Genzyme Receives FDA Response Letter on Synvisc-One(TM)
Date:11/13/2007

.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including Genzyme's expectation for receipt of US marketing approval of Synvisc-One and the revised timing thereof, its belief that a single-injection regimen of Synvisc will simplify pain management, provide additional patient convenience, reduce costs and expand the viscosupplementation market, and Genzyme's plans to pursue marketing approvals in additional jurisdictions. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, among others, Genzyme's ability to adequately respond to the questions raised by the FDA and to do so in a timely fashion, the extent to which the FDA determines that Synvisc-One can appropriately be approved for marketing in the US, the extent to which the government and private insurers recognize the benefits of Synvisc-One and maintain or otherwise implement reimbursement policies that reflect these benefits, and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
2. Delaware Court Approves Bioenvision, Genzyme Joint Petition
3. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
4. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
5. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
6. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
7. DaVita Receives Civil Complaint
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
10. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... M.D., a second-year resident in the Department of ... Medicine and Health Sciences, received at $154K grant ... presence of diffuse brain swelling and injury in ... epidemiological studies, intracerebral hemorrhage accounts for less than ... least treatable form of stroke, with the highest ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
(Date:9/19/2014)... Capital Region Periodontics and Dental Implants, led ... the latest addition to their treatment options for ... dental implants. Often referred to as the “gentle ... factor normally associated with traditional gum surgery. No ... this procedure a very attractive oral surgery alternative ...
(Date:9/19/2014)... receive any palliative care, reveals new research to be ... in Madrid, Spain, 26-30 September. The findings are astonishing ... new oncology centres in Europe, Canada, South America and ... Designated Centre of Integrated Oncology and Palliative Care., , ... the Institute of Oncology Bucharest, Romania, member of the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Follow ... part of the medical imaging market, are engineered to ... developments over the past three decades have expanded the ... barium and iodine based agents used for over half ... and radiopharmaceuticals, imaging agents have witnessed sea changes, revolutionizing ...
Breaking Medicine News(10 mins):Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4
... Calif., Jan. 15 Alpine Biomed,Corporation, a global ... has acquired Stellate Systems Inc. Headquartered in ... of advanced,neurodiagnostic systems. The acquisition is the ... Healthcare Partners, a leading private equity,firm focused exclusively ...
... action ,precautionary, as salmonella outbreak probe continues; 5 deaths ... states , , THURSDAY, Jan. 15 (HealthDay News) -- Cereal ... popular Keebler and Austin brand peanut butter crackers, ... nationwide salmonella outbreak that is linked to peanut butter. ...
... Motivation with a Value-Filled Option for Customers to Become ... help motivated consumers quit smoking and to further its ... prescription medications, Walmart today announced that it has expanded ... prescription starter pack for $9, the lowest price on ...
... Cancer patients in Estonia ... intensity modulated radiotherapy (IMRT), for the first time with ... Varian Medical Systems treatment machine at the North ... opening ceremony attracted publicity on Estonian national TV and ...
... (azelastine hydrochloride) Nasal Spray Hits U.S. Pharmacies SOMERSET, ... new medication is available to manage the symptoms ... as many as 40 million people in the ... in a unique vehicle formulated for enhanced patient ...
... to Portable Medical RecordsSCOTTSDALE, Ariz. and FAIRFAX, Va., ... Data Systems Analysts (DSA) are pleased to announce ... customers with even higher levels of security and ... Memory,s flagship product is a physician-designed system to ...
Cached Medicine News:Health News:Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market 2Health News:Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market 3Health News:Kellogg Halts Sales of Peanut Butter Crackers 2Health News:Kellogg Halts Sales of Peanut Butter Crackers 3Health News:Walmart Offers $9 Smoking Cessation Starter Pack 2Health News:Walmart Offers $9 Smoking Cessation Starter Pack 3Health News:Estonian Cancer Patients Have Access to More Conformal Radiotherapy Treatments for First Time with Unveiling of Advanced Varian Treatment Machine 2Health News:Estonian Cancer Patients Have Access to More Conformal Radiotherapy Treatments for First Time with Unveiling of Advanced Varian Treatment Machine 3Health News:Allergy Sufferers to Benefit from New, Improved Rapid Relief Medication This Spring 2Health News:Allergy Sufferers to Benefit from New, Improved Rapid Relief Medication This Spring 3Health News:Allergy Sufferers to Benefit from New, Improved Rapid Relief Medication This Spring 4Health News:My Medical Memory and Data Systems Analysts Partner to Provide Secure, Portable Health Records 2Health News:My Medical Memory and Data Systems Analysts Partner to Provide Secure, Portable Health Records 3
(Date:9/19/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... XIAFLEX ® in the U.S. and XIAPEX ® ... Wegman , will present a corporate overview at the 21 ... The presentation will take place on Friday, ... Broadway Hotel in New York, NY . ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... and Staff Will Focus on Advances in ... and Treatment of Lung Cancer in Women, SEATTLE, Sept. ... the Society for Women,s Health,Research, the Lung Cancer Alliance and ... Matters to Research," on,Capitol Hill to discuss advances in the ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... clinical development and discovery,programs at four upcoming investor conferences: ... Presentation: Monday, September 17, 2007 at 10:00 a.m. Pacific ... the St. Regis Hotel in San Francisco ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill 3Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: